We need material for 30 samples. The largest cost is lab consumables: DNA extraction kits, library-prep reagents, and QC chemicals, totaling $8,000. These materials allow us to isolate cfDNA and prepare each sample for sequencing with consistent quality. Transport of biological samples requires temperature-controlled courier services; the $1,000 allocated covers packaging and same-day delivery to preserve cfDNA integrity. We also need sterile single-use blood-taking kits for all dogs, costing 4,000, which include needles, stabilizing tubes, and antiseptic materials needed for safe and standardized collection. To ensure each sample meets sequencing requirements, $4,000 is allocated for electrophoresis gels, quantification reagents, and dyes. Finally, $2,000 supports computing and software for data storage, processing, and quality-control analysis. This budget reflects the minimum required to generate reliable validation data for our test.

Additional Information

CaniSense Light is tailored for veterinary oncology. The test analyzes short cfDNA fragments shed by tumors, capturing mutational and epigenetic signatures undetectable by imaging or physical exams. This scientific foundation creates a scalable diagnostic engine for multi-cancer detection and beyond, for other diseases and other animals.

The science generated from this project and others at testblu can be used in human diagnostics too.

The Fronters that we push are in three levels:
1- technology: how to leverage AI to make the best prediction from available Data
2-Data generation: how to efficiently generate the necessary biological data with sufficient quality for effective AI implementation.
3- Quick validation of AI-platforms in veterinary-first model: This is a win-win approach, as the veterinarian space can use the cutting edge technology, the validation can be used to speed-up the application also in the human space.

10-Year Vision of testblu diagnostics (2035)

testblu’s vision is to become the leading AI-powered precision diagnostics platform in veterinary medicine—and a proven bridge between animal and human health.

1. From Veterinary Screening to One Health Impact

By 2035, testblu will not only define early cancer screening as a standard of care for dogs, but also serve as a validated translational platform for human oncology and diagnostics. Because dogs develop cancer naturally, faster, and with strong biological similarities to humans, our large-scale real-world datasets will enable:

• Translational insights for human liquid biopsy research

• Cross-species biomarker discovery

• Strategic collaborations with human diagnostics, pharma, and research institutions

testblu will operate at the intersection of veterinary diagnostics and human health (“One Health”).

2. From Cancer Detection to Multi-Disease Precision Diagnostics

We will evolve from a multi-cancer screening company into a broad disease-agnostic diagnostics platform, scaling our AI and liquid biopsy infrastructure to:

• Oncology (30+ cancers)

• Inflammatory and immune-mediated diseases

• Metabolic and age-related disorders

• Therapy response and disease monitoring

Our platform architecture is designed to reuse data, workflows, and AI models across disease domains, enabling efficient expansion with strong margins.

3. Multi-Species Expansion at Global Scale

Starting with dogs, testblu will systematically scale to:

• Cats (first expansion)

• Additional companion animals

• Selected livestock and research-relevant species, where clinically and economically justified

This positions testblu as a species-agnostic diagnostics platform, not a single-product company.

4. Global Standard of Care in Preventive Veterinary Medicine

By 2035, testblu aims to make blood-based preventive screening a routine annual check-up, embedded into veterinary workflows worldwide through:

• Veterinary clinic networks

• Diagnostic distributors

• Pet insurance integrations

Our tests will be trusted clinical decision tools, not experimental add-ons.

5. Data, AI, and Long-Term Value Creation

Through continuous data generation across diseases and species, testblu will build one of the largest proprietary cfDNA and clinical outcome datasets in veterinary medicine, creating:

• A defensible AI moat

• Increasing diagnostic accuracy over time

• Long-term strategic value for M&A, licensing, and human-health partnerships

The Long-Term Impact

By 2035, testblu will:

• Extend healthy life expectancy for millions of animals

• Reduce emotional and financial burden for pet owners

• Enable earlier, more precise veterinary interventions

• Contribute meaningfully to human cancer research and diagnostics through translational data

In essence: testblu’s 10-year vision is to transform veterinary diagnostics into a proactive, AI-driven, multi-disease, multi-species platform—and to translate those insights into human health.

If you want, I can now:

• Compress this into a 1-paragraph “vision slide”

• Create a short investor soundbite

• Adapt it specifically for EU grants, VCs, or pharma partnerships